...
首页> 外文期刊>Trials >Development of the IRIS-AR strategy: an intervention to improve rates of accrual and retention for the VTE-PRO randomized controlled trial
【24h】

Development of the IRIS-AR strategy: an intervention to improve rates of accrual and retention for the VTE-PRO randomized controlled trial

机译:虹膜战略的发展:一种提高vte-pro随机对照试验的增强和保留率的干预

获取原文

摘要

The Venous Thromboembolism Prophylaxis (VTE-PRO) randomized trial is a pilot study evaluating the impact of extended-duration prophylaxis on venous thromboembolic events in patients undergoing lung cancer resection. Enrolled VTE-PRO participants self-inject either low-molecular weight heparin or a saline placebo for 30?days postoperatively. Study outcomes include feasibility, incidence of venous thromboembolism,?and venous thromboembolism-related morbidity and mortality. Initial analyses demonstrated low rates of accrual and retention for the VTE-PRO pilot. Therefore, the purpose of the current study was to develop a knowledge translation intervention to improve VTE-PRO pilot trial accrual and retention. Eligible participants were surveyed to identify the barriers to VTE-PRO participation. The Theoretical Domains Framework was used to categorize these barriers. Barriers were mapped to the capabilities, opportunities, and behavior (COM-B) behavioral change wheel to identify potential interventions to support trial accrual and retention. The resulting knowledge translation intervention was titled Inform, Remind, Involve and Support to improve Accrual and Retention (IRIS-AR). Key informant interviews with patients were held to refine and confirm the validity of identified barriers and perceived acceptability of the proposed IRIS-AR intervention. Institutional Review Board approval was granted for this study. The resulting intervention included: information booklets and counseling sessions to identify unique participant challenges to trial participation (Inform); daily reminders to administer injections (Remind); involvement of family/caregivers in study processes (Involve); and leverage of an existing home-care nursing program to provide injection support when needed (Support). Twenty-six key informant participants were interviewed. The most common barriers to trial participation included lack of social support and fear of needle injection. Participants generally supported use of information booklets, involvement of family/caregivers, and support by a home-care nursing program; however, not all supported the use of daily reminders. Developed using theory and integrated knowledge translation, the IRIS-AR presents a patient-centered intervention that leverages existing programs to promote trial engagement. The proposed strategy can likely be adapted to improve compliance with other patient-directed interventions. ClinicalTrials.gov, NCT02334007 . Registered on 8 January 2015.
机译:静脉血栓栓塞预防(VTE-Pro)随机试验是一种试验研究,评估延长持续时间预防对肺癌切除患者静脉血栓栓塞事件的影响。注册VTE-Pro参与者自我注射低分子量肝素或盐水安慰剂30.术后一天。研究结果包括可行性,静脉血栓栓塞的发病率,α和静脉血栓栓塞相关的发病率和死亡率。初始分析显示VTE-Pro Pilot的低应计和保留率。因此,目前研究的目的是制定知识翻译干预,以改善VTE-Pro试验试验应计和保留。调查符合条件的参与者以确定VTE-Pro参与的障碍。理论域框架用于对这些障碍进行分类。屏障被映射到能力,机会和行为(COM-B)行为改变轮以确定支持试验应计和保留的潜在干预措施。由此产生的知识翻译干预题为“通知”,提醒,涉及和支持,以改善应计和保留(IRIS-AR)。与患者的重点线路访谈进行细化,并确认所确定的障碍的有效性,并感知拟议的IRIS-AR干预的可接受性。本研究授予机构审查委员会批准。由此产生的干预包括:信息小册子和咨询会议,以确定审判参与的独特参与者挑战(通知);每日提醒给管理注射(提醒);家庭/护理人员参与研究过程(涉及);并利用现有的家庭护理护理计划在需要时提供注入支撑(支持)。采访了二十六个关键信息。审判参与最常见的障碍包括缺乏社会支持和对针注射的恐惧。参与者普遍支持使用信息小册子,家庭/看护人的参与,以及由家庭护理护理计划的支持;但是,并非所有人都支持使用日常提醒。使用理论和综合知识翻译制定,IRIS-AR呈现患者以患者为中心的干预,利用现有计划促进审判参与。拟议的策略可能适应改善遵守其他患者导向的干预措施。 ClinicalTrials.gov,NCT02334007。 2015年1月8日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号